Critical Reviews in Oncology / Hematology
Volume 74 , Pages S2-S6 , April 2010

The anti-tumor effect of bisphosphonates ABCSG-12, ZO-FAST and more …

  • Michael Gnant

      Affiliations

    • Medical University of Vienna; Austrian Breast & Colorectal Cancer Group, Austria
    • Corresponding Author InformationCorresponding authors. Professor Michael Gnant MD. Department of Surgery, Medical University of Vienna, Waehringer Guertel 18–20, A-1090 Vienna, Austria
    • ,
  • Holger Eidtmann

      Affiliations

    • University Medical Center Schleswig-Holstein, Germany
    • Corresponding Author InformationHolger Eidtmann M.D. Dep of Ob/Gyn, Campus Kiel, University Medical Center Schleswig-Holstein, Germany

References 

  1. Winter MC , Holen I , Coleman RE . Exploring the anti-tumor activity of bisphosphonates in early breast cancer . Cancer Treat Rev . 2008;34:453–475
  2. Santini D , Martini F , Fratto ME , et al.   In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients . Cancer Immunol Immunother . 2009;58:31–38
  3. Gnant M . Onco Target Ther . 2009;2:95–104
  4. Meads MB , Hazlehurst LA , Dalton WS . The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance . Clin Cancer Res . 2008;14:2519–2526
  5. Diel IJ , Jaschke A , Solomayer EF , et al.   Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up . Ann Oncol . 2008;12:2007–2011
  6. Saarto T , Blomqvist C , Virkkunen P , Elomaa I . Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial . J Clin Oncol . 2001;19:10–17
  7. Powles T , Paterson A , McCloskey E , et al.   Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer . Breast Cancer Res . 2006;8:R13
  8. Curtis JR , Westfall AO , Cheng H , Lyles K , Saag KG , Delzell E . Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users . J Bone Miner Res . 2008 Sep;23(9):1435–1441
  9. Yuasa T , Kimura S , Ashihara E , Habuchi T , Maekawa T . Zoledronic acid - a multiplicity of anti-cancer action . Curr Med Chem . 2007;14(20):2126–2135
  10. Alakangas A , Selander K , Mulari M , et al.   Alendronate disturbs vesicular trafficking in osteoclasts . Calcif Tissue Int . 2002;70:40–47
  11. Gnant M , Mlineritsch B , Schippinger W , et al.   Endocrine therapy plus zoledronic acid in premenopausal breast cancer . N Engl J Med . 2009;360:679–691
  12. Gnant M , Mlineritsch B , Luschin-Ebengreuth G , et al.   Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group . J Clin Oncol . 2007;25:820–828
  13. Gnant M , Mlineritsch B , Luschin-Ebengreuth G , et al.   Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy . Lancet Oncol . 2008;9:840–849
  14. Eidtmann H, Bundred N, De Boer R, et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving letrozole: 36 months follow-up of ZO-FAST. Presented at 31st San Antonio Breast Cancer Symposium, December 10–14, 2008, San Antonio, TX. Abstract 44.
  15. Brufsky A , Bundred N , Coleman R , et al.   Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole . Oncologist . 2008;13:503–514
  16. Coleman RE . Effect of anastrozole on bone mineral density: 5-year results from the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial . J Clin Oncol . 2006;24(18 suppl):5s; Abstract 511.
  17. Perez EA . Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer . Ann Oncol . 2007;18(suppl 8):26–35 viii
  18. Bundred NJ , Campbell ID , Davidson N , et al.   Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results . Cancer . 2008;112(5):1001–1010
  19. Paget S . Secondary growth in cancer of breast . Lancet . 1889;571
  20. Coleman R , Gnant M . New results from the use of bisphosphonates in cancer patients . Curr Opin Supp Palliat Care . 2009;3:213–218
  21. Mittal S , Mifflin R , Powell DW . Cancer stem cells: the other face of Janus . Am J Med Sci . 2009;338:107–112

PII: S1040-8428(10)70003-2

doi: 10.1016/S1040-8428(10)70003-2

Critical Reviews in Oncology / Hematology
Volume 74 , Pages S2-S6 , April 2010

Article Tools